AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34233458
Drug: Glucose derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose derivative treatment
Trial: 34233992
Drug: Treatment pathways
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment pathways for knee OA
Trial: 34235085
Drug: EphA2-redirected CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EphA2-redirected CAR T-cells (starting dosage 1×10)
Trial: 34236298
Drug: Training in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training in opioid treatment as peer recovery support service interventionists
Trial: 34236401
Drug: PLX9486 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX9486 at 500 mg or less
Trial: 34236401
Drug: PLX9486 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX9486 at 1000 mg
Trial: 34236401
Drug: PLX9486 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX9486 at 500 mg or less with sunitinib
Trial: 34236401
Drug: PLX9486 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX9486 and sunitinib combination (25 or 37.5 mg)
Trial: 34236525
Drug: Lying position
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lying position (LyP) for 30 minutes daily during the first 7 days of hospitalization
Trial: 34236995
Drug: Pfizer-BioNTech COVID-19
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech COVID-19 vaccine (first dose)
Trial: 34236995
Drug: Pfizer-BioNTech COVID-19
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech COVID-19 vaccine (second dose)
Trial: 34236995
Drug: Pfizer-BioNTech COVID-19
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech COVID-19 vaccine (both doses)
Trial: 34237031
Drug: Selpercatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selpercatinib combined with 131I therapy
Trial: 34240339
Drug: Dasatinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (60 or 80 mg/m2)
Trial: 34241781
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 21 days until progressive disease, unacceptable adverse event, or completion of 24 months of treatment.
Trial: 34242221
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue (SAT) index
Trial: 34242388
Drug: Panobinostat (PANO)
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat (PANO) 5 mg orally 3 times a week for 26 weeks, starting on day -5, in combination with tacrolimus and sirolimus.
Trial: 34243799
Drug: Protamine administration
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine administration
Trial: 34244298
Drug: Multiplexed engineering
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplexed engineering approach using lentiviruses for CAR T-cell immunotherapy
Trial: 34244325
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous doses of phosphorus
Trial: 34246328
Drug: Nomograms developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomograms developed from predictors including time since initial diagnosis, chemotherapy status, baseline haemoglobin concentration.
Trial: 34246461
Drug: Remimazolam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam 0.1 mg/kg (single bolus) in hepatic impairment trial
Trial: 37942930
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) treatment
Trial: 34248840
Drug: Hyperinsulinemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic clamp with induced normoglycemia (4.5 ± 0.07 mmol/L for 1 hour) in T2D
Trial: 34248841
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (ACEi) therapies in T2D subjects
Trial: 34249763
Drug: Intravitreal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal methotrexate (MTX, 400 μg, 0.1 mL) injections for 1 year (total 16 injections) and six cycles of rituximab (375 mg/m2).
Trial: 34250266
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of tranexamic acid
Trial: 34250266
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of tranexamic acid
Trial: 34250266
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tranexamic acid
Trial: 34250553
Drug: Seribantumab 40/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seribantumab 40/20 mg/kg (loading dose followed by maintenance dose)
Trial: 34250553
Drug: Seribantumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seribantumab (various doses: 3.2, 6, 10, 15, or 20 mg/kg weekly)
Trial: 34251649
Drug: Aprocitentan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan (up to 600 mg single dose and 100 mg once daily at multiple doses)
Trial: 34252125
Drug: Sequential organ
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential organ failure assessment (SOFA) score
Trial: 34253172
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/day until disease progression or other withdrawal criteria
Trial: 34253376
Drug: Locoregional melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locoregional melphalan chemotherapy (hyperthermic isolated limb perfusion)
Trial: 34253376
Drug: Locoregional melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locoregional melphalan chemotherapy (isolated limb infusion)
Trial: 34253376
Drug: Locoregional melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locoregional melphalan chemotherapy
Trial: 34253577
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg twice daily until disease progression or unacceptable toxicity
Trial: 34253587
Drug: Donor-specific HLA
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor-specific HLA antibody (DSA) positivity in NR biopsies
Trial: 34253733
Drug: AAV2-hAADC delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-hAADC delivered via convection-enhanced delivery (CED) to the bilateral substantia nigra (SN) and ventral tegmental area (VTA) with a total infusion volume of 80 µL per hemisphere.
Trial: 34253928
Drug: HER2-specific CAR
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2-specific CAR T cells via locoregional infusion
Trial: 34255063
Drug: Iodine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing supplement initiated prepregnancy and continued through pregnancy
Trial: 34255063
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of supplement
Trial: 34255078
Drug: Phytoglycogen (PHY)
RxNorm normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoglycogen (PHY) at 0.5 g·min-1
Trial: 34255078
Drug: Phytoglycogen (PHY)
RxNorm normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoglycogen (PHY) at 1.0 g·min-1
Trial: 34255078
Drug: Phytoglycogen (PHY)
RxNorm normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoglycogen (PHY) at 1.5 g·min-1
Trial: 34255078
Drug: Phytoglycogen (PHY)
RxNorm normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoglycogen (PHY) at 2 g·min-1
Trial: 34255140
Drug: Anti-inflammatory treatment
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory treatment initiated or increased
Trial: 34255140
Drug: Treatment increased
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment increased
Trial: 34255140
Drug: Anti-inflammatory therapy
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory therapy increased
Trial: 34255535
Drug: BEMPEG 0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years
Trial: 34255555
Drug: Food Supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food Supplement with Antioxidative Santa Herba Extract
Trial: 34255727
Drug: VoiceAdapt mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VoiceAdapt mobile therapy app, used for 5 weeks of training.
Trial: 34256279
Drug: Alisertib 40
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 40 mg BID on D1-3 per week plus nab-paclitaxel 100 mg/m²
Trial: 34256732
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer patients receiving immunotherapy
Trial: 34256967
Drug: Guideline recommendations
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline recommendations for first- to nth-line treatment of target mental health symptoms.
Trial: 34256967
Drug: Approach to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approach to prescribing guidelines that incorporates real-world availability of treatments.
Trial: 34259164
Drug: Web-based psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychotherapy plus treatment as usual (8 weeks)
Trial: 34259164
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual exclusively
Trial: 34259664
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (gas flow 0; 30-60 L/min)
Trial: 34260435
Drug: Bilateral Cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral Cochlear Implants (BiCI)
Trial: 34261508
Drug: E-MOTIVE bundle
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-MOTIVE bundle (1) Early PPH detection using a calibrated drape, (2) uterine Massage, (3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, (6) genital tract Examination and escalation when necessary.
Trial: 34261794
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of RAR-related orphan receptor-positive LTi cells
Trial: 34262403
Drug: Dydrogesterone 10
RxNorm normalized name: dydrogesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg twice daily orally for 21 days (day 5-25 of each menstrual cycle) for 4 cycles
Trial: 34262514
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT)-based preventive group intervention: EMOTION
Trial: 34263020
Drug: PR-T 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-T 0.2 mg/kg/d (Arm 1)
Trial: 34263020
Drug: PR-T 0.15-0.175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2)
Trial: 34263020
Drug: PR-T 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3)
Trial: 34263213
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (n=30), applied three times a week for the first 2 weeks
Trial: 34263665
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous treatments)
Trial: 34263738
Drug: Granulocyte CSF
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granulocyte CSF (G-CSF), S100A8, IL-6
Trial: 34264412
Drug: LY3076226 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3076226 at doses ranging from 0.2-5.0 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle.
Trial: 34264732
Drug: Integrated cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cannabis and anxiety reduction treatment (ICART)
Trial: 34265048
Drug: 9-valent HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent HPV (9vHPV) vaccine types
Trial: 34265285
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brush cytology, MI_H, MI_N, and CA19-9
Trial: 34265394
Drug: High-field MR-Linac
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-field MR-Linac treatment
Trial: 34265433
Drug: Ensartinib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib at a dose of 225 mg once daily
Trial: 34268426
Drug: Adjunctive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatments including types of oxygen support, ventilation, rescue therapies for hypoxemia, other adjunctive and supportive treatments, experimental therapies
Trial: 34268623
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 ng/mL
Trial: 34268623
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 ng/mL
Trial: 34268623
Drug: Dexmedetomidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.5 ng/mL
Trial: 34268711
Drug: IMC-001 (PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMC-001 (PD-L1 blocker) administered intravenously every 2 weeks at doses ranging from 2 to 20 mg/kg
Trial: 34269152
Drug: Acalabrutinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib and Vistusertib combination therapy
Trial: 34269698
Drug: Liquid chromatography-tandem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid chromatography-tandem mass spectrometry method for monitoring medication adherence
Trial: 34269927
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (IV-TCZ) 4 mg/kg
Trial: 34270347
Drug: Continuous Glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Glucose Monitors and Insulin Pumps
Trial: 38861398
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Trial: 34271312
Drug: IDH1-vac, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDH1-vac, a long IDH1R132H peptide vaccine
Trial: 34272204
Drug: Palliative systemic
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative systemic treatment (usual care arm of GAP 70+ Trial)
Trial: 34272204
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of ≥second line of chemotherapy
Trial: 34272724
Drug: Treatment withdrawal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment withdrawal after 180 days
Trial: 34273485
Drug: Biologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic treatment
Trial: 34273485
Drug: Maintenance systemic
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance systemic corticosteroids or uncontrolled by high-dosage inhaled corticosteroids
Trial: 34273526
Drug: Transplant ePROM
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant ePROM (TXP) administered via mobile application
Trial: 34273904
Drug: Secukinumab treatment
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab treatment for 52 weeks
Trial: 34274393
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with sequential S-1
Trial: 34274536
Drug: CD5-targeting fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5-targeting fully human heavy-chain variable (FHV) CAR-T therapy
Trial: 34274536
Drug: Standard CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CAR-T therapy (implied control)
Trial: 34275061
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose proton pump inhibitor (PPI) therapy for 4 weeks
Trial: 34275336
Drug: Measurements of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurements of serum drug concentrations
Trial: 34275403
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg by intravenous infusion on Day 1 of 3-week cycles (maximum 16 cycles)
Trial: 34275469
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of breathing rate with Fourier coefficients, signal amplitude, and/or ARIMA coefficients
Trial: 34276537
Drug: Dopamine Receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine Receptor D1
Trial: 34277393
Drug: Neoadjuvant Endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Endocrine Therapy (NET) with gonadotropin-releasing hormone agonist and tamoxifen
Trial: 34277393
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy (NCT) with adriamycin plus cyclophosphamide followed by taxane
Trial: 34277393
Drug: Neoadjuvant Endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Endocrine Therapy (NET)
Trial: 34277437
Drug: Hormone measurements
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone measurements post HSCT (FSH and AMH)
Trial: 34278053
Drug: Stereotactic radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiation therapy (30 Gy in 5 fractions) for patients with 24 and 30 lesions.
Trial: 34278053
Drug: Stereotactic radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiation therapy (12 Gy in 2 fractions) for the patient with 50 targets.
Trial: 34278053
Drug: Stereotactic radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiation therapy treatment plans using volumetric modulated arc therapy.
Trial: 34278100
Drug: Dyed sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dyed sucralfate gel
Trial: 34278169
Drug: selonsertib, firsocostat,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations
Trial: 34280258
Drug: Ibrutinib (BTK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (BTK inhibitor)
Trial: 34280258
Drug: Asparaginase (ASNase)
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase (ASNase) therapy
Trial: 34280257
Drug: WT1-TCB antibody
RxNorm normalized name: TCB-008
DrugBank: TCB-008 (DB18352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1-TCB antibody